We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 48 of 67 for:    lyme

Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00237016
Recruitment Status : Completed
First Posted : October 12, 2005
Last Update Posted : October 24, 2008
Information provided by:
Medical Corps, Israel Defense Force

Brief Summary:

Abstract Background Tick-Borne Relapsing Fever (TBRF) is an acute febrile illness. In Israel, TBRF is caused by Borrelia persica and is transmitted by Ornithodoros tholozani ticks. We examined the safety and efficacy of a post exposure treatment policy to prevent TBRF.

Methods In a double blind, placebo controlled trial 93 healthy volunteers with suspected tick exposure (51 with bite signs and 42 contacts) were randomly assigned to receive either Doxycycline (200 mg for the first day and 100mg/d for 4 days) or placebo, approximately 2 days after contact. Blood smears were examined for Borrelia at inclusion and during fever rise. Serology for Lyme disease cross- reactivity and PCR for Borrelia GlpQ gene were also performed. Cases of TBRF were defined as subjects having fever and a positive blood smear.

Condition or disease Intervention/treatment Phase
Relapsing Fever, Tick-Borne Jarisch Herxheimer Reaction Drug: doxycycline treatment Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Official Title: Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever
Study Start Date : April 2002
Estimated Study Completion Date : April 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fever
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • suspected exposure to tick-borne relapsing fever
  • after returning from field exercise in a tick-borne relapsing fever infected area
  • having a tick bite or staying in field in close proximity to a subject with tick bite sign

Exclusion Criteria:

  • known sensitivity to tetracycline or doxycycline
  • febrile illness on recruitment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00237016

Israel Defence Forces
Tel Hashomer, Israel
Sponsors and Collaborators
Medical Corps, Israel Defense Force
Principal Investigator: Tal Hasin, MD Medical corps, Israel Defence Forces

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00237016     History of Changes
Other Study ID Numbers: RF1
First Posted: October 12, 2005    Key Record Dates
Last Update Posted: October 24, 2008
Last Verified: April 2003

Additional relevant MeSH terms:
Relapsing Fever
Body Temperature Changes
Signs and Symptoms
Borrelia Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Tick-Borne Diseases
Spirochaetales Infections
Anti-Bacterial Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents